KY 0901
Alternative Names: KY-0901Latest Information Update: 28 Oct 2025
At a glance
- Originator Novatim Immune Therapeutics (Zhejiang)
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 16 Oct 2025 Preclinical trials in Solid tumours in China (Parenteral)